Raynaud's phenomenon, also called Raynaud's syndrome or disease, is a condition where blood vessels in the fingers and toes (and sometimes in the earlobes, nose, and lips) constrict and cause the skin to turn a pale or a patchy red to blue. It is usually triggered by cold or emotional stress. Episodes are intermittent and may last minutes or hours. The condition affects about 5 - 10% of the U.S. population, and it affects women five times more often than men. It usually occurs between the ages of 20 - 40 in women and later in life in men. It can exist alone (primary Raynaud's) or in conjunction with other conditions (such as scleroderma, lupus, and rheumatoid arthritis).
No one knows what causes primary Raynaud's phenomenon. Risk factors include the following:
Your health care provider may conduct several blood tests, such as the antinuclear antibody test and the erythrocyte sedimentation rate (ESR), to look for connective tissue disease or other autoimmune disorders. If you have primary Raynaud's phenomenon, your health care provider will most likely begin with a conservative approach involving nondrug and self-help measures (for example, dressing warmly, avoiding the cold, controlling stress).
One of the most important preventive measures you can take is to stop smoking because nicotine shrinks arteries and decreases blood flow. Other preventive measures include the following:
These actions are often enough to manage Raynaud's phenomenon.
Several types of drugs are used to treat Raynaud's phenomenon. Calcium-channel blockers can reduce the frequency and severity of attacks, but the effects are small, about three to five fewer attacks per week. Your doctor may also recommend vasodilators (drugs that open up blood vessels). A powerful antioxidant agent, N-acetylcysteine, has been shown to decrease the frequency and severity of Raynaud's phenomenon. Researchers believe that N-acetylcysteine seems to act as an effective vasodilator in the treatment of Raynaud's phenomenon.
In severe cases, a surgical procedure called sympathectomy, which severs the nerves that control constriction of the blood vessels, may be used.
Herbs are generally a safe way to strengthen and tone the body's systems. As with any therapy, you should work with your health care provider to diagnose your problem before starting any treatment. You may use herbs as dried extracts (capsules, powders, teas), glycerites (glycerine extracts), or tinctures (alcohol extracts). Unless otherwise indicated, make teas with 1 tsp. herb per cup of hot water. Steep covered 5 - 10 minutes for leaf or flowers, and 10 - 20 minutes for roots. Drink 2 - 4 cups per day. You may use tinctures alone or in combination as noted.
The following herbs are circulatory stimulants with other properties as well. Take 20 - 30 drops two times per day.
Homeopathy may be useful as a supportive therapy.
Hydrotherapy consists of the expert application of water at differing temperatures to various body parts to increase circulation and oxygenation. Because of the potential for complications in Raynaud's phenomenon, hydrotherapy treatments should be done only under the supervision of a licensed naturopathic physician and in conjunction with your regular doctor.
Although no major studies have looked at the effectiveness of acupuncture in treating Raynaud's syndrome, acupuncture may increase blood flow and decrease pain in some patients.
Most milder cases can be controlled through self-help measures.
Many drugs used to treat Raynaud's phenomenon can affect a growing fetus and should not be used by pregnant women. Mild-to-severe depressive symptoms are common so patients should be carefully monitored. Migraine is also significantly increased in patients with Raynaud's phenomenon.
Balch JF, Balch PA. Prescription for Nutritional Healing. 2nd ed. Garden City Park, NY: Avery Publishing Group; 1997.
Batchelder HJ. Allopathic specific condition review: Raynaud's disease. Protocol J Botan Med. 1996;2:134-137.
Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) as a treatment for cold-induced vasospasm (Raynaud's phenomenon). Prog Lipid Res. 1986;25:335-340.
Beretta L, Astori S, Ferrario E, Caronni M, Raimondi M, Scorza R. Determinants of depression in 111 Italian patients with systemic sclerosis. Reumatismo. 2006;58(3):219-25.
DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study Am J Med 1989;86:158-64
Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill; 1998.
Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980-2985.
Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology. 2005;44(5):587-96.
Mitchell W, Batchelder HJ. Naturopathic specific condition review: Raynaud's disease. Protocol J Botan Med. 1996;2:138-140.
Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.Vasc Med. 2002;7:265-7.
Salsano F, Letizia C, Proietti M, Rossi C, Proietti AR, Rosato E, Pisarri S. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud's phenomenon. Int J Immunopathol Pharmacol. 2005;18(4):761-70.
Sunderkotter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology. 2006;45(Supple):iii33-iii35.
Sunderland, GT, Belch JJ, Sturrock RD, et al. A double-blind randomised placebo-controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol. 1988;7:46-49.
Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. Rheumatololgy. 2005;44(2):145-50.
Tierney LM Jr, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis & Treatment 1999. 38th ed. Stamford, Conn: Appleton & Lange; 1999.